Investing.com23d agobullish
Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key dataInvesting.com -- Truist Securities upgraded Biogen to Buy from Hold and raised its price target to $235 from $190, citing growing confidence in the company’s Alzheimer’s and immunology pipeline ahead of several major clinical data readouts over the next two years.